Membrelor
Membrelor is a fictional small-molecule therapeutic agent described in hypothetical medical literature as an oral inhibitor of a novel intracellular kinase involved in T‑cell activation. In this imagined framework, it is designed to dampen pathogenic immune responses by limiting activation and proliferation of autoreactive lymphocytes, with the aim of treating autoimmune and inflammatory diseases.
Mechanism of action: Membrelor is described as selectively inhibiting the intracellular kinase MRTK-3, thereby blocking downstream
Medical uses and status: Within the fictional account, membrelor is investigated for autoimmune diseases including rheumatoid
Pharmacology and development: Reported pharmacokinetic properties include moderate oral bioavailability and a half-life compatible with once-daily